Literature DB >> 29563959

Bilateral Optic Nerve Involvement Combined with Unilateral Facial Palsy in a Patient with Acute Myeloid Leukaemia: A Case Report.

Suk-Yeon Lee1, Seung-Hyun Kim1, Suk-Gyu Ha1.   

Abstract

Central nervous system (CNS) involvement, including optic nerve involvement, in a patient with acute myeloid leukaemia (AML) is an extremely rare condition. We report a case of bilateral optic nerve involvement combined with unilateral facial palsy in a patient with AML who achieved complete remission following allogenic peripheral blood stem cell transplantation as a young patient. After further evaluation, the patient was diagnosed with a recurrence of AML with CNS involvement. The presentation of multiple types of CNS involvement in AML may be suspicious evidence of AML recurrence.

Entities:  

Keywords:  Acute myeloid leukemia; bilateral; central nerve system; facial palsy; optic neuropathy

Year:  2017        PMID: 29563959      PMCID: PMC5858855          DOI: 10.1080/01658107.2017.1362444

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  10 in total

1.  Ocular involvement in leukemia and allied disorders.

Authors:  R A ALLEN; B R STRAATSMA
Journal:  Arch Ophthalmol       Date:  1961-10

2.  The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.

Authors:  C Castagnola; A Nozza; A Corso; C Bernasconi
Journal:  Haematologica       Date:  1997 Sep-Oct       Impact factor: 9.941

3.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

4.  Analysis of 135 autopsy eyes for ocular involvement in leukemia.

Authors:  N J Leonardy; M Rupani; G Dent; G K Klintworth
Journal:  Am J Ophthalmol       Date:  1990-04-15       Impact factor: 5.258

5.  Ocular involvement in leukemia--a study of 288 cases.

Authors:  S C Reddy; N Jackson; B S Menon
Journal:  Ophthalmologica       Date:  2003 Nov-Dec       Impact factor: 3.250

6.  A prospective ophthalmic evaluation of patients with acute myeloid leukemia: correlation of ocular and hematologic findings.

Authors:  J W Karesh; E J Goldman; K Reck; S E Kelman; E J Lee; C A Schiffer
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

7.  Orbital and ocular manifestations of acute childhood leukemia: clinical and statistical analysis of 180 patients.

Authors:  V Russo; I U Scott; G Querques; A Stella; A Barone; N Delle Noci
Journal:  Eur J Ophthalmol       Date:  2008 Jul-Aug       Impact factor: 2.597

Review 8.  Ocular and orbital involvement in leukemia.

Authors:  M C Kincaid; W R Green
Journal:  Surv Ophthalmol       Date:  1983 Jan-Feb       Impact factor: 6.048

9.  Outcome of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with central nervous system involvement.

Authors:  Jun Aoki; Ken Ishiyama; Shuichi Taniguchi; Takahiro Fukuda; Kazuteru Ohashi; Hiroyasu Ogawa; Heiwa Kanamori; Tetsuya Eto; Koji Iwato; Hisashi Sakamaki; Yasuo Morishima; Tokiko Nagamura; Yoshiko Atsuta; Akiyoshi Takami
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-06       Impact factor: 5.742

10.  Ophthalmic manifestations of acute and chronic leukemias presenting to a tertiary care center in India.

Authors:  Jacob Koshy; M Joseph John; Satish Thomas; Gurvinder Kaur; Nitin Batra; Wilson J Xavier
Journal:  Indian J Ophthalmol       Date:  2015-08       Impact factor: 1.848

  10 in total
  2 in total

1.  Chemotherapy as Treatment for Acute Myeloid Leukemia (AML)-Induced Facial Nerve Palsy.

Authors:  Michael Fana; Brook Centofanti; Philip Kuriakose
Journal:  Cureus       Date:  2022-03-31

2.  Unilateral isolated optic nerve infiltration combined with central retinal artery occlusion in a patient with acute myeloid leukemia.

Authors:  Chen Zhao; Duo Wei; Xuan Shi; Mingwei Zhao
Journal:  Am J Ophthalmol Case Rep       Date:  2022-03-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.